DE68922614D1 - Antisense-oligonukleotide gegen c-myb proto-oncogene und deren verwendungen. - Google Patents

Antisense-oligonukleotide gegen c-myb proto-oncogene und deren verwendungen.

Info

Publication number
DE68922614D1
DE68922614D1 DE68922614T DE68922614T DE68922614D1 DE 68922614 D1 DE68922614 D1 DE 68922614D1 DE 68922614 T DE68922614 T DE 68922614T DE 68922614 T DE68922614 T DE 68922614T DE 68922614 D1 DE68922614 D1 DE 68922614D1
Authority
DE
Germany
Prior art keywords
oncogenes
oligonucleotides
antisense
myb
myb proto
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
DE68922614T
Other languages
English (en)
Other versions
DE68922614T2 (de
Inventor
Alan Gewirtz
Bruno Calabretta
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Temple University of Commonwealth System of Higher Education
Original Assignee
Temple University of Commonwealth System of Higher Education
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Temple University of Commonwealth System of Higher Education filed Critical Temple University of Commonwealth System of Higher Education
Publication of DE68922614D1 publication Critical patent/DE68922614D1/de
Application granted granted Critical
Publication of DE68922614T2 publication Critical patent/DE68922614T2/de
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/82—Translation products from oncogenes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1135—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against oncogenes or tumor suppressor genes
DE68922614T 1988-11-07 1989-11-03 Antisense-oligonukleotide gegen c-myb proto-oncogene und deren verwendungen. Expired - Fee Related DE68922614T2 (de)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US26790188A 1988-11-07 1988-11-07
US40802689A 1989-09-15 1989-09-15
US07/427,659 US5098890A (en) 1988-11-07 1989-10-27 Antisence oligonucleotides to c-myb proto-oncogene and uses thereof
PCT/US1989/004927 WO1990005445A1 (en) 1988-11-07 1989-11-03 Antisense oligonucleotides to c-myb proto-oncogene and uses thereof

Publications (2)

Publication Number Publication Date
DE68922614D1 true DE68922614D1 (de) 1995-06-14
DE68922614T2 DE68922614T2 (de) 1996-01-11

Family

ID=27402019

Family Applications (1)

Application Number Title Priority Date Filing Date
DE68922614T Expired - Fee Related DE68922614T2 (de) 1988-11-07 1989-11-03 Antisense-oligonukleotide gegen c-myb proto-oncogene und deren verwendungen.

Country Status (7)

Country Link
US (1) US5098890A (de)
EP (1) EP0424476B1 (de)
AT (1) ATE122234T1 (de)
AU (1) AU641636B2 (de)
DE (1) DE68922614T2 (de)
DK (1) DK3591D0 (de)
WO (1) WO1990005445A1 (de)

Families Citing this family (130)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5831066A (en) * 1988-12-22 1998-11-03 The Trustees Of The University Of Pennsylvania Regulation of bcl-2 gene expression
US6841541B1 (en) 1992-02-21 2005-01-11 The Trustees Of The University Of Pennsylvania Regulation of BCL-2-gene expression
US5087617A (en) * 1989-02-15 1992-02-11 Board Of Regents, The University Of Texas System Methods and compositions for treatment of cancer using oligonucleotides
US5248671A (en) * 1989-02-15 1993-09-28 Board Of Regents, The University Of Texas System Methods and compositions for treatment of cancer using oligonucleotides
US5959096A (en) * 1992-03-16 1999-09-28 Isis Pharmaceuticals, Inc. Antisense oligonucleotides against human protein kinase C
US6339066B1 (en) 1990-01-11 2002-01-15 Isis Pharmaceuticals, Inc. Antisense oligonucleotides which have phosphorothioate linkages of high chiral purity and which modulate βI, βII, γ, δ, Ε, ζ and η isoforms of human protein kinase C
US20040142899A1 (en) * 1990-01-11 2004-07-22 Isis Pharmaceuticals, Inc. Compositions and methods for enhanced biostability and altered biodistribution of oligonucleotides in mammals
US6753423B1 (en) 1990-01-11 2004-06-22 Isis Pharmaceuticals, Inc. Compositions and methods for enhanced biostability and altered biodistribution of oligonucleotides in mammals
US5149797A (en) * 1990-02-15 1992-09-22 The Worcester Foundation For Experimental Biology Method of site-specific alteration of rna and production of encoded polypeptides
IE911115A1 (en) * 1990-04-10 1991-10-23 Canji Inc Gene therapy for cell proliferative diseases
US5271941A (en) * 1990-11-02 1993-12-21 Cho Chung Yoon S Antisense oligonucleotides of human regulatory subunit RI.sub.α of cAMP-dependent protein kinases
US5242906A (en) * 1991-04-22 1993-09-07 University Of North Carolina At Chapel Hill Antisense oligonucleotides against Epstein-Barr virus
CA2109829A1 (en) * 1991-05-23 1992-11-26 Bruno Calabretta Treatment of colorectal carcinoma with antisense oligonucleotides to c-myb proto-oncogene
JPH06508622A (ja) * 1991-06-18 1994-09-29 テンプル　ユニバーシティ−オブ　ザ　コモンウェルス　システム　オブ　ハイヤーエデュケーション ｂｃｒ−ａｂ１アンチセンスオリゴヌクレオチドによる白血球増殖の選択的抑制
JPH07501204A (ja) * 1991-06-28 1995-02-09 マサチューセッツ インスティテュート オブ テクノロジー 局所的オリゴヌクレオチド療法
EP0558697A1 (de) * 1991-06-28 1993-09-08 Massachusetts Institute Of Technology Lokale oligonukleotiden Behandlung
AU2449092A (en) * 1991-08-09 1993-03-02 New England Deaconess Hospital A method of inducing hemoglobin synthesis in red blood cells and uses therefor
US6335434B1 (en) 1998-06-16 2002-01-01 Isis Pharmaceuticals, Inc., Nucleosidic and non-nucleosidic folate conjugates
ATE191567T1 (de) * 1991-10-31 2000-04-15 Matritech Inc Bestimmung von nukleären matrixproteinen in flüssigkeiten
WO1993009789A1 (en) * 1991-11-15 1993-05-27 Temple University - Of The Commonwealth System Of Higher Education Treatment of melanoma with antisense oligonucleotides to c-myb proto-oncogene
US8153602B1 (en) 1991-11-19 2012-04-10 Isis Pharmaceuticals, Inc. Composition and methods for the pulmonary delivery of nucleic acids
JPH06511387A (ja) 1991-12-24 1994-12-22 アイシス・ファーマシューティカルス・インコーポレーテッド β−アミロイド調節のための組成物および方法
JP2731630B2 (ja) * 1992-02-19 1998-03-25 ベイラー・カレッジ・オブ・メディスン 細胞増殖のオリゴヌクレオチドの変調
US5922686A (en) * 1992-03-16 1999-07-13 Isis Pharmaceuticals, Inc. Oligonucleotide modulation of protein kinase C
US5885970A (en) * 1992-03-16 1999-03-23 Isis Pharmaceuticals, Inc. Antisense oligonucleotides against human protein kinase C
US5681747A (en) * 1992-03-16 1997-10-28 Isis Pharmaceuticals, Inc. Nucleic acid sequences encoding protein kinase C and antisense inhibition of expression thereof
US6117847A (en) * 1992-03-16 2000-09-12 Isis Pharmaceuticals, Inc. Oligonucleotides for enhanced modulation of protein kinase C expression
US5916807A (en) * 1992-03-16 1999-06-29 Isis Pharmaceuticals, Inc. Antisense oligonucleotides against human protein kinase C
JP2635216B2 (ja) * 1992-03-16 1997-07-30 アイシス・ファーマシューティカルス・インコーポレーテッド プロテインキナーゼｃのオリゴヌクレオチド調節
US5882927A (en) * 1992-03-16 1999-03-16 Isis Pharmaceuticals, Inc. Oligonucleotide inhibition of protein kinase C
US6537973B1 (en) 1992-03-16 2003-03-25 Isis Pharmaceuticals, Inc. Oligonucleotide inhibition of protein kinase C
US5948898A (en) * 1992-03-16 1999-09-07 Isis Pharmaceuticals, Inc. Methoxyethoxy oligonucleotides for modulation of protein kinase C expression
US6153599A (en) * 1992-03-16 2000-11-28 Isis Pharmaceuticals, Inc. Methoxyethoxy oligonucleotides for modulation of protein kinase C expression
US5643780A (en) * 1992-04-03 1997-07-01 Isis Pharmaceuticals, Inc. Compositions and methods for modulating RNA activity through modification of the 5' cap structure of RNA
US5936079A (en) 1992-04-06 1999-08-10 Alton Ochsner Medical Foundation Oligonucleotide which binds to a chromosomal binding site for p53 protein
US6599505B1 (en) * 1992-04-10 2003-07-29 Research Development Foundation Immunotoxins directed against CD33 related surface antigens
JPH07509602A (ja) * 1992-06-22 1995-10-26 マトリテク　インコーポレイテッド 新規な悪性細胞型内部核マトリックスマーカー
US5646042A (en) * 1992-08-26 1997-07-08 Ribozyme Pharmaceuticals, Inc. C-myb targeted ribozymes
AU5136693A (en) * 1992-10-01 1994-04-26 Thomas Jefferson University Antisense oligonucleotides to b myb proto-oncogene
US5985558A (en) 1997-04-14 1999-11-16 Isis Pharmaceuticals Inc. Antisense oligonucleotide compositions and methods for the inibition of c-Jun and c-Fos
IL108367A0 (en) * 1993-01-27 1994-04-12 Hektoen Inst For Medical Resea Antisense polynzcleotide inhibition of human growth factor-sensitive cancer cells
US5395825A (en) * 1993-03-10 1995-03-07 Yale University Fertility regulation with transforming growth factor β
US5468629A (en) * 1993-04-13 1995-11-21 Calhoun; Cornelia Method of promoting in vitro homologous recombination transfection in mammalian cells using the RecA protein
ATE438723T1 (de) * 1993-05-27 2009-08-15 Univ Washington Cyclisch gmp bindende cyclisch gmp spezifische phosphodiesterase materialien und verfahren
US5473060A (en) * 1993-07-02 1995-12-05 Lynx Therapeutics, Inc. Oligonucleotide clamps having diagnostic applications
US5571903A (en) * 1993-07-09 1996-11-05 Lynx Therapeutics, Inc. Auto-ligating oligonucleotide compounds
US7326783B2 (en) * 1993-07-10 2008-02-05 Biognostik Gesellschaft Fur Biomolekulare Diagnostik Mbh Pharmaceutical composition comprising antisense-nucleic acid for prevention and/or treatment of neuronal injury, degeneration and cell death and for the treatment of neoplasms
US5417978A (en) * 1993-07-29 1995-05-23 Board Of Regents, The University Of Texas System Liposomal antisense methyl phosphonate oligonucleotides and methods for their preparation and use
DE69433036T2 (de) 1993-09-03 2004-05-27 Isis Pharmaceuticals, Inc., Carlsbad Aminoderivatisierte nukleoside und oligonukleoside
JP2001505401A (ja) * 1993-09-20 2001-04-24 シー． リード，ジョン ｂｃ１−２遺伝子発現の調節
US5807838A (en) * 1994-09-23 1998-09-15 Isis Pharmaceuticals, Inc. Oligonucleotide modulation of multidrug resistance-associated protein
US5510239A (en) * 1993-10-18 1996-04-23 Isis Pharmaceuticals, Inc. Oligonucleotide modulation of multidrug resistance-associated protein
US6399376B1 (en) 1993-11-05 2002-06-04 Isis Pharmaceuticals, Inc. Modulation of vascular cell adhesive molecule expression through oligonucleotide interactions
US5618709A (en) * 1994-01-14 1997-04-08 University Of Pennsylvania Antisense oligonucleotides specific for STK-1 and method for inhibiting expression of the STK-1 protein
US5814619A (en) * 1994-04-08 1998-09-29 Isis Pharmacuticals, Inc. Oligonucleotide inhibition of P120
US6090626A (en) * 1994-05-31 2000-07-18 Isis Pharmaceuticals Inc. Antisense oligonucleotide modulation of raf gene expression
KR100211178B1 (ko) * 1994-05-31 1999-07-15 파샬 비. 린네 라프유전자 발현의 안티센스 올리고뉴클레오티드 조절
US20030119769A1 (en) * 1994-05-31 2003-06-26 Monia Brett P Antisense oligonucleotide modulation of raf gene expression
US6358932B1 (en) 1994-05-31 2002-03-19 Isis Pharmaceticals, Inc. Antisense oligonucleotide inhibition of raf gene expression
US5563255A (en) * 1994-05-31 1996-10-08 Isis Pharmaceuticals, Inc. Antisense oligonucleotide modulation of raf gene expression
US5744362A (en) * 1994-05-31 1998-04-28 Isis Pharmaceuticals, Inc. Antisense oligonucleotide modulation of raf gene expression
US6410518B1 (en) 1994-05-31 2002-06-25 Isis Pharmaceuticals, Inc. Antisense oligonucleotide inhibition of raf gene expression
US5656612A (en) * 1994-05-31 1997-08-12 Isis Pharmaceuticals, Inc. Antisense oligonucleotide modulation of raf gene expression
US20060142236A1 (en) * 1994-05-31 2006-06-29 Isis Pharmaceuticals, Inc. Antisense oligonucleotide modulation of raf gene expression
US5994320A (en) * 1995-02-06 1999-11-30 Regents Of The University Of Minnesota Antisense oligonucleotides and methods for treating central nervous system tumors
US5830658A (en) * 1995-05-31 1998-11-03 Lynx Therapeutics, Inc. Convergent synthesis of branched and multiply connected macromolecular structures
US5855911A (en) * 1995-08-29 1999-01-05 Board Of Regents, The University Of Texas System Liposomal phosphodiester, phosphorothioate, and P-ethoxy oligonucleotides
US8043835B1 (en) 1996-03-26 2011-10-25 Oncomedx, Inc. Methods for detecting and monitoring cancer using extracellular RNA
US7785842B2 (en) * 1996-03-26 2010-08-31 Oncomedx, Inc. Comparative analysis of extracellular RNA species
WO1997035589A1 (en) 1996-03-26 1997-10-02 Kopreski Michael S Method enabling use of extracellular rna extracted from plasma or serum to detect, monitor or evaluate cancer
US6759217B2 (en) * 1996-03-26 2004-07-06 Oncomedx, Inc. Method enabling use of extracellular RNA extracted from plasma or serum to detect, monitor or evaluate cancer
US5856099A (en) * 1996-05-21 1999-01-05 Isis Pharmaceuticals, Inc. Antisense compositions and methods for modulating type I interleukin-1 receptor expression
US5858683A (en) * 1996-08-30 1999-01-12 Matritech, Inc. Methods and compositions for the detection of cervical cancer
US6977244B2 (en) * 1996-10-04 2005-12-20 Board Of Regents, The University Of Texas Systems Inhibition of Bcl-2 protein expression by liposomal antisense oligodeoxynucleotides
US6001991A (en) * 1996-10-04 1999-12-14 Isis Pharmaceuticals Inc. Antisense oligonucleotide modulation of MDR P-glycoprotein gene expression
US6319906B1 (en) 1996-12-31 2001-11-20 Isis Pharmaceuticals Oligonucleotide compositions and methods for the modulation of the expression of B7 protein
US6077833A (en) * 1996-12-31 2000-06-20 Isis Pharmaceuticals, Inc. Oligonucleotide compositions and methods for the modulation of the expression of B7 protein
US7235653B2 (en) * 1996-12-31 2007-06-26 Isis Pharmaceuticals, Inc. Oligonucleotide compositions and methods for the modulation of the expression of B7 protein
US20040023917A1 (en) * 1996-12-31 2004-02-05 Bennett C. Frank Oligonucleotide compositions and methods for the modulation of the expression of B7 protein
US20070009934A1 (en) * 1997-03-14 2007-01-11 Kopreski Michael S Method enabling use of extracellular RNA extracted from plasma or serum to detect, monitor or evaluate cancer
US8440396B2 (en) * 1997-03-14 2013-05-14 Oncomedx, Inc. Method enabling use of extracellular RNA extracted from plasma or serum to detect, monitor or evaluate cancer
AU6578298A (en) 1997-03-21 1998-10-20 President And Fellows Of Harvard College Antisense inhibition of angiogenin expression
AU731909B2 (en) 1997-07-01 2001-04-05 Isis Pharmaceuticals, Inc. Compositions and methods for the delivery of oligonucleotides via the alimentary canal
US20070149472A1 (en) * 1997-08-13 2007-06-28 Mckay Robert Antisense oligonucleotide compositions and methods for the modulation of jnk proteins
US5877309A (en) 1997-08-13 1999-03-02 Isis Pharmaceuticals, Inc. Antisense oligonucleotides against JNK
US6809193B2 (en) 1997-08-13 2004-10-26 Isis Pharmaceuticals, Inc. Antisense oligonucleotide compositions and methods for the modulation of JNK proteins
US6133246A (en) * 1997-08-13 2000-10-17 Isis Pharmaceuticals Inc. Antisense oligonucleotide compositions and methods for the modulation of JNK proteins
US7704962B1 (en) 1997-10-03 2010-04-27 Board Of Regents, The University Of Texas System Small oligonucleotides with anti-tumor activity
US7285288B1 (en) 1997-10-03 2007-10-23 Board Of Regents, The University Of Texas System Inhibition of Bcl-2 protein expression by liposomal antisense oligodeoxynucleotides
DE69939367D1 (de) 1998-01-12 2008-10-02 Felder Robin A G protein-verwandte kinasemutanten in der essentiellen hypertonie
AU745880B2 (en) * 1998-05-21 2002-04-11 Isis Pharmaceuticals, Inc. Compositions and methods for non-parenteral delivery of oligonucleotides
US20060204989A1 (en) * 1998-09-22 2006-09-14 Kopreski Michael S Comparative analysis of extracellular RNA species
US20080261292A1 (en) * 1998-09-22 2008-10-23 Oncomedx, Inc. Method Enabling the Use of Extracellular Ribonucleic Acid (RNA) Extracted from Plasma or Serum to Detect, Monitor or Evaluate Cancer or Premalignant Conditions
US8163524B2 (en) * 1998-09-22 2012-04-24 Oncomedx, Inc. Comparative analysis of extracellular RNA species
US6656730B1 (en) 1999-06-15 2003-12-02 Isis Pharmaceuticals, Inc. Oligonucleotides conjugated to protein-binding drugs
US20030181412A1 (en) * 1999-12-21 2003-09-25 Ingeneus Corporation Method for modifying transcription and/or translation in an organism for therapeutic, prophylactic and/or analytic uses
AU2001263810A1 (en) * 2000-03-27 2001-10-08 Bayer Aktiengesellschaft Regulation of human c-myb-related genes
EP1158055A1 (de) 2000-05-26 2001-11-28 Xu Qi University of Teaxs Laboratoire de Leucémie Chen Verfahren zur Diagnose von Krebs
PT1295611E (pt) * 2000-06-20 2010-09-14 Dainippon Sumitomo Pharma Co Preparações para transferência de oligonucleótidos
US7795232B1 (en) 2000-08-25 2010-09-14 Genta Incorporated Methods of treatment of a bcl-2 disorder using bcl-2 antisense oligomers
US20040147473A1 (en) * 2000-11-10 2004-07-29 Warrell Raymond P. Methods of treatment of a bcl-2 disorder using bcl-2 antisense oligomers
KR100426453B1 (ko) 2000-11-28 2004-04-13 김진우 인간 자궁경부암 2 원암 유전자 및 이에 의해 코딩되는단백질, 이를 포함하는 발현벡터 및 이 벡터로 형질전환된세포
EP1392366A4 (de) * 2001-04-13 2005-01-19 Population Council Inc Kernrezeptor-vermittelte einführung eines pna proteins in zellkerne
DK1407787T3 (da) * 2001-06-20 2009-06-02 Dainippon Sumitomo Pharma Co Fremgangsmåde til fremme af nukleinsyreoverförsel
US20030096770A1 (en) * 2001-07-11 2003-05-22 Krotz Achim H. Enhancement of the stability of oligonucleotides comprising phosphorothioate linkages by addition of water-soluble antioxidants
DE60239470D1 (de) * 2001-07-25 2011-04-28 Oncomedx Inc Verfahren zur bewertung pathologischer krankheitszustände unter verwendung extrazellulärer rna
US20030049203A1 (en) * 2001-08-31 2003-03-13 Elmaleh David R. Targeted nucleic acid constructs and uses related thereto
US20100159464A1 (en) * 2001-11-05 2010-06-24 Oncomedx, Inc. Method for Detection of DNA Methyltransferase RNA in Plasma and Serum
US20030104454A1 (en) * 2001-11-05 2003-06-05 Kopreski Michael S. Method for detection of DNA methyltransferase RNA in plasma and serum
ATE416183T1 (de) 2002-02-01 2008-12-15 Univ Mcgill Oligonukleotide mit alternierenden segmenten und deren verwendungen
US20030191075A1 (en) * 2002-02-22 2003-10-09 Cook Phillip Dan Method of using modified oligonucleotides for hepatic delivery
WO2004071453A2 (en) 2003-02-13 2004-08-26 Isis Pharmaceuticals, Inc. Compositions and methods for treatment of pouchitis
WO2004092407A1 (en) * 2003-04-17 2004-10-28 Genesis Group Inc. Pygopus in diagnosis and treatment of cancer
ATE446791T1 (de) * 2003-05-16 2009-11-15 Univ Laval Cns chlorid-modulierung und verwendung derselben
US7897582B2 (en) * 2003-05-23 2011-03-01 Isis Pharmaceuticals, Inc. Oligonucleotide compositions and methods for the modulation of the expression of B7 protein
US7960355B2 (en) * 2003-05-23 2011-06-14 Isis Pharmaceuticals, Inc. Compositions and methods for the modulation of the expression of B7 protein
US20050020526A1 (en) * 2003-06-03 2005-01-27 Cytogenix, Inc. Oligodeoxynucleotide intervention for prevention and treatment of sepsis
US20040248101A1 (en) * 2003-06-03 2004-12-09 Cytogenix, Inc. Identification of novel antibacteria agents by screening the single-stranded DNA expression library
EP1696034A4 (de) * 2003-12-19 2006-12-27 Dainippon Sumitomo Pharma Co Neues verfahren zum nukleinsäuretransfer
AU2005244036A1 (en) * 2004-05-14 2005-11-24 Universite De Laval Phospholipase C gamma modulation and uses thereof for management of pain and nociception
US7700272B2 (en) * 2004-06-09 2010-04-20 Mcgill University Polynucleotides encoding acetylcholine-gated chloride channel subunits of Caenorhabditis elegans
US20090062184A1 (en) * 2005-03-24 2009-03-05 Dainippon Sumitomo Pharma Co., Ltd. Fine particulate preparation comprising complex of nucleic acid molecule and collagen
AU2007281082A1 (en) * 2006-08-04 2008-02-07 Isis Pharmaceuticals, Inc. Compositions and methods for the modulation of JNK proteins
WO2008092099A2 (en) * 2007-01-26 2008-07-31 Rosetta Genomics, Ltd. Compositions and methods for treating hematopoietic malignancies
US20090136942A1 (en) * 2007-09-18 2009-05-28 Oncomedx, Inc. Analysis of Extracellular RNA
WO2009046483A1 (en) * 2007-10-08 2009-04-16 The Walter And Eliza Hall Institute Of Medical Research Therapeutic protocol for the treatment or prevention of thrombocytopenia
EP2432499A2 (de) 2009-05-20 2012-03-28 Schering Corporation Modulation von pilr-rezeptoren zur behandlung mikrobieller infektionen
US8691227B2 (en) 2009-12-17 2014-04-08 Merck Sharp & Dohme Corp. Methods of treating multiple sclerosis, rheumatoid arthritis and inflammatory bowel disease using agonists antibodies to PILR-α
JP6794258B2 (ja) 2013-09-30 2020-12-02 ジェロン・コーポレーションＧｅｒｏｎ Ｃｏｒｐｏｒａｔｉｏｎ オリゴヌクレオチドについてのホスホロジアミデート骨格結合
LT3189074T (lt) 2014-09-05 2021-06-10 Rsem, Limited Partnership Kompozicijos ir būdai skirti uždegimo gydymui ir prevencijai

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ209840A (en) * 1983-10-17 1988-11-29 Kaji Akira A method of inhibiting viral propagation by hybridising dna with the viral rna thus blocking its action

Also Published As

Publication number Publication date
AU5035090A (en) 1990-06-12
EP0424476A4 (en) 1992-05-06
EP0424476B1 (de) 1995-05-10
ATE122234T1 (de) 1995-05-15
WO1990005445A1 (en) 1990-05-31
AU641636B2 (en) 1993-09-30
DE68922614T2 (de) 1996-01-11
EP0424476A1 (de) 1991-05-02
DK3591D0 (da) 1991-01-09
US5098890A (en) 1992-03-24

Similar Documents

Publication Publication Date Title
DE68922614D1 (de) Antisense-oligonukleotide gegen c-myb proto-oncogene und deren verwendungen.
US5446137B1 (en) Oligonucleotides containing 4'-substituted nucleotides
NZ289028A (en) Use of antisense nucleic acids in the treatment of skin disease
IT9083334A0 (it) Procedimento per l'estrazione e la purificazione di dna genomico umano
EP1905304A3 (de) Behandlung von Neoplasmen mit Viren
EP0219830A3 (en) Hair treating composition containing cationic organic polymer and carboxyfunctional silicone
HK164395A (en) Use of 3'-azido-3'-deoxythymidine in the treatment or prophylaxis of human retroviral infections
DE69828892D1 (de) Verwendung von uridin-5'-diphosphat und analoge zur behandlung von lungenerkrankungen
EE03512B1 (et) Epinastiin kasutamiseks valude ravis
DE69739758D1 (de) Vakzine zur behandlung von lymphomen und leukämie
GB9019946D0 (en) Treatment of nucleotide material
HUP0100786A3 (en) Substituted 2-phenyl-1-(3,4-dihydroxy-5-nitrophenyl)-1-ethanones, their use in the treatment of some central and peripheral nervous system disorders and pharmaceutical compositions containing them
DE69715482D1 (de) Herstellung von 1,1,1,3,3-Pentachlorbutan und von 1,1,1,3,3-Pentafluorbutan
EE9600018A (et) 2,9-diasendatud puriin-6-oonid, nende valmistamismeetod, kasutamine ravimite valmistamiseks ja nimetatud ühendeid sisaldavad ravimid
HUP9903249A3 (en) Combinations comprising vx478, zidovudine, ftc and/or 3tc for use in the treatment of hiv
FI940139A0 (fi) Alkenyyliryhmiä sisältäviä siloksaanikopolymeerejä, niiden valmistus ja käyttö
DE69116810T2 (de) Fluoralkylgruppe enthaltende Organosiliciumoligomer, Verfahren zu deren Herstellung und Oberflächenbehandlungsmittel
EP1079764A4 (de) Behandlung sexueller störungen bei bestimmten patientengruppen
IT1241123B (it) Cellule umane per l'elevata espressione di geni inseriti in dna ricombinanti episomiali,loro preparazione e loro impiego
NL193614B (nl) Werkwijze voor de bereiding van 4,5-tri- en -tetramethyleen-4-isothiazoline-3-onen, 2-alkyl- of -aralkylthio-1-cycloalkeencarbonamiden ten gebruike bij deze werkwijze en werkwijze voor de bereiding van de 2-alkyl- of -aralkylthio-1-cycloalkeencarbonamiden.
PL337665A1 (en) (s) 2-methylamine-2-phenyl-n-butyl-3,4,5-trimethoxybezoate and application thereof in treating long-lasting pains
CA2004364A1 (en) Antisense oligonucleotides to c-myb oncogene and uses thereof
HU9903098D0 (en) Combinations comprising vx478, zidovudine and/or 1592u89 for use in the treatment of hiv
Salmon Endoscopic treatment of gastro-intestinal tumours: can surgery be avoided?
EP0410393A3 (en) Polysiloxane copolymer useful for hair treating

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
8339 Ceased/non-payment of the annual fee